Kiniksa Pharmaceuticals International vs Travere Therapeutics
KNSA and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KNSA and TVTX compare
Kiniksa Pharmaceuticals International is the larger company, worth 3.0 times as much as Travere Therapeutics ($14.4B against $4.7B).
Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus 58.9% for Kiniksa Pharmaceuticals International).
Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 9.6% compared with −7.4% at Travere Therapeutics.
Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 6 for Travere Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KNSA | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $14.4B | $4.7B |
| Share price | $92.24 | $50.39 |
| Change, 1 year | 147% | 68.1% |
| Change, 5 years | 526% | 67.4% |
| Beta (5Y) | 0.34 | 1.14 |
| Employees | 366 | 497 |
| StockData Score | ||
| Total score | 14 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 95.1× | – |
| P/S | 17.1× | 8.0× (better) |
| P/B | 22.0× (better) | 194× |
| EV/EBITDA | 136× (better) | 194× |
| P/FCF | 78.7× | – |
| FCF yield | 1.3% | – |
| Fair value | $11.65 | $5.96 |
| Margin of safety | −692% (better) | −745% |
| Growth | ||
| Revenue growth (TTM) | 58.9% | 77.1% (better) |
| Revenue growth, 5Y average | – | 19.9% |
| Net income growth (TTM) | 1584% | – |
| EPS growth (TTM) | 2325% | – |
| Profitability | ||
| Gross margin | 89.8% | 98.6% (better) |
| Operating margin | 11.9% (better) | −6.8% |
| Net margin | 9.6% (better) | −7.4% |
| FCF margin | 21.7% | – |
| Return on equity | 14.0% (better) | −152% |
| Return on invested capital | 44.9% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −4.3× |
| Current ratio | 3.90 | 4.05 (better) |
| Altman Z-score | 37.02 (better) | 2.24 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 30.1% | 112% |
| Held by insiders | 4.7% | 1.6% |
| Insider net buying, 12 months | −$44.8M (better) | −$99.7M |
| Short interest, % of float | 2.5% | 13.6% |
Go deeper
- KNSA stock overview
- KNSA income statement
- KNSA valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.